Search

Your search keyword '"Galetta, D."' showing total 837 results
Start Over Author "Galetta, D."
837 results on '"Galetta, D."'

151. Chemotherapy-induced nausea and vomiting (CINV) in patients with stage III/IV lung cancer during the first-line treatment: assessment by physician, nurse and patient. Preliminary results from an Italian multicenter survey

Author

Carnio, S., primary, Galetta, D., additional, Scotti, V., additional, Cortinovis, D.L., additional, Antonuzzo, A., additional, Pisconti, S., additional, Rossi, A., additional, Martelli, O., additional, Cecere, F.L., additional, Bria, E., additional, Del Conte, A., additional, Pegoraro, V., additional, Montagna, E.S., additional, Topulli, J., additional, Pelizzoni, D., additional, Rapetti, S.G., additional, Gianetta, M., additional, and Novello, S., additional

Published
2016
Full Text
View/download PDF

152. The role of health professionals in informing patients with pulmonary diseases to stop smoking: final data of an Italian multicentric survey

Author

Demichelis, S., primary, Rapetti, S.G., additional, Galetta, D., additional, Catino, A., additional, Ricci, D., additional, Moretti, A.M., additional, Bria, E., additional, Pilotto, S., additional, Bruno, A., additional, Valmadre, G., additional, Bandelli, G.P., additional, Trisolini, R., additional, Gianetta, M., additional, Pacchiana, M.V., additional, Vallone, S., additional, and Novello, S., additional

Published
2016
Full Text
View/download PDF

153. Molecular profiling in advanced non-small-cell lung cancer: preliminary data of the Italian observational prospective study

Author

Gobbini, E., primary, Grecorc, V., additional, Galetta, D., additional, Riccardi, F., additional, Tiseo, M., additional, Scotti, V., additional, Ceribelli, A., additional, Buffoni, L., additional, Maiello, E., additional, Delmonte, A., additional, Franchina, T., additional, Migliorino, M.R., additional, Cortinovis, D., additional, Pisconti, S., additional, Di Maio, M., additional, Graziano, P., additional, Bria, E., additional, Rossi, G., additional, Rossi, A., additional, and Novello, S., additional

Published
2016
Full Text
View/download PDF

156. Italian clinical research in non-small-cell lung cancer

Author

GRIDELLI C, ROSSI A, GALETTA D, MAIONE P, FERRARA C, GUERRIERO C, DEL GAIZO, F, NICOLELLA D, COLANTUONI G, GEBBIA, Vittorio, COLUCCI G., GRIDELLI C, ROSSI A, GALETTA D, MAIONE P, FERRARA C, GUERRIERO C, DEL GAIZO, NICOLELLA D, COLANTUONI G, GEBBIA V, and COLUCCI G

Subjects
Male, Oncology, medicine.medical_specialty, Poor prognosis, Lung Neoplasms, NSCLC, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Lung cancer, neoplasms, Aged, Clinical Trials as Topic, Lung, business.industry, Standard treatment, Cancer, Hematology, medicine.disease, Italian clinical research, respiratory tract diseases, Survival Rate, Clinical trial, Treatment Outcome, Clinical research, medicine.anatomical_structure, Italy, Chemotherapy, Adjuvant, Female, Radiotherapy, Adjuvant, Non small cell, Cisplatin, business
Abstract

Lung cancer is the most common cause of cancer deaths in both men and women worldwide and has a poor prognosis. Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Surgery is the only curative treatment of NSCLC but only 15–20% of tumours can be radically resected with a survival of about 40% at 5 years. Considering these disappointing results NSCLC is one of the most frequent subjects of clinical research worldwide. Italy is playing an important role in the clinical research of NSCLC performing phase I, II and III trials, prevalently by cooperative groups, and achieving important results that contributed to define the standard treatment for NSCLC patients. In particular, Italy is leader in the clinical research of the treatment of advanced NSCLC elderly patients. Today, large controlled clinical trials are ongoing. In this paper we analyse and discuss the main trials performed by Italian groups in the fields of NSCLC.

Published
2005

157. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study

Author

Maione, P, Perrone, F, Gallo, C, Manzione, L, Piantedosi, F, Barbera, S, Cigolari, S, Rosetti, F, Piazza, E, Robbiati, Sf, Bertetto, O, Novello, S, Migliorino, Mr, Favaretto, A, Spatafora, M, Ferraù, F, Frontini, L, Bearz, A, Repetto, L, Gridelli, C, Barletta, E, Barzelloni, Ml, Iaffaioli, Rv, DE MAIO, E, DI MAIO, M, DE FEO, G, Sigoriello, G, Chiodini, P, Cioffi, A, Guardasole, V, Angelini, V, Rossi, A, Bilancia, D, Germano, D, Lamberti, A, Pontillo, V, Brancaccio, L, Renda, F, Romano, F, Esani, G, Gambaro, A, Vinante, O, Azzarello, G, Clerici, M, Bollina, R, Belloni, P, Sannicolò, M, Ciuffreda, L, Parello, G, Cabiddu, M, Sacco, C, Sibau, A, Porcile, G, Castiglione, F, Ostellino, O, Monfardini, S, Stefani, M, Scagliotti, G, Selvaggi, G, DE MARINIS, F, Martelli, O, Gasparini, G, Morabito, A, Gattuso, D, Colucci, G, Galetta, D, Giotta, F, Gebbia, V, Borsellino, N, Testa, A, Malaponte, E, Capuano, Ma, Angiolillo, M, Sollitto, F, Tirelli, U, Spazzapan, S, Adamo, V, Altavilla, G, Scimone, A, Hopps, Mr, Tartamella, F, Ianniello, Gp, Tinessa, V, Failla, G, Bordonaro, R, Gebbia, N, Valerio, Mr, D'Aprile, M, Veltri, E, Tonato, M, Darwish, S, Romito, S, Carrozza, F, Barni, S, Ardizzoia, A, Corradini, Gm, Pavia, G, Belli, M, Colantuoni, G, Galligioni, E, Caffo, O, Labianca, R, Quadri, A, Cortesi, Enrico, D'Auria, Giuliana, Fava, S, Calcagno, A, Luporini, G, Locatelli, Mc, DI COSTANZO, F, Gasperoni, S, Isa, L, Candido, P, Gaion, F, Palazzolo, G, Nettis, G, Annamaria, A, Rinaldi, M, Lopez, M, Felletti, R, DI NEGRO GB, Rossi, N, Calandriello, A, Maiorino, L, Mattioli, R, Celano, A, Schiavon, S, Illiano, A, Raucci, Ca, Caruso, M, Foa, P, Tonini, G, Curcio, C, Cazzaniga, M., MAIONE P, PERRONE F, GALLO C, MANZIONE L, PIANTEDOSI F, BARBERA S, CIGOLARI, ROSETTI F, PIAZZA E, ROBBIATI SF, BERTETTO O, NOVELLO S, MIGLIORINO MR, FAVARETTO A, SPATAFORA M, FERRAU F, FRONTINI L, BEARZ A, REPETTO L, GRIDELLI C, BARLETTA E, BARZELLONI ML, IAFFAIOLI RV, DE MAIO E, DI MAIO M, DE FEO G, SIGORIELLO G, CHIODINI P, CIOFFI A, GUARDASOLE V, ANGELINI V, ROSSI A, BILANCIA, GERMANO D, LAMBERTI A, PONTILLO V, BRANCACCIO L, RENDA F, ROMANO F, ESANI G, GAMBARO A, VINANTE O, AZZARELLO G, CLERICI M, BOLLINA R, BELLONI P, SANNICOLO M, CIUFFREDA L, PARELLO G, CABIDDU M, SACCO C, SIBAU A, PORCILE G, CASTIGLIONE F, OSTELLINO O, MONFARDINI S, STEFANI M, SCAGLIOTTI G, SELVAGGI G, DE MARINIS F, MARTELLI O, GASPARINI G, MORABITO A, GATTUSO D, COLUCCI G, GALETTA D, GIOTTA F, GEBBIA V, ET AL, Maione, P, Perrone, F, Gallo, Ciro, Manzione, L, Piantedosi, F, Barbera, S, Cigolari, S, Rosetti, F, Piazza, E, Robbiati, Sf, Bertetto, O, Novello, S, Migliorino, Mr, Favaretto, A, Spatafora, M, Ferrau, F, Frontini, L, Bearz, A, Repetto, L, and Gridelli, C.

Subjects
Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Activities of daily living, Health Status, carcinoma, Vinblastine, Vinorelbine, Deoxycytidine, older people, Quality of life, Instrumental activitie, Carcinoma, Non-Small-Cell Lung, Internal medicine, Activities of Daily Living, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Lung cancer, Aged, Aged, 80 and over, validation, Proportional hazards model, business.industry, QLQ-C30, Age Factors, Cancer, clinical trial, Prognosis, medicine.disease, Gemcitabine, Comorbidity, humanities, comorbidity, Oncology, Quartile, Quality of Life, Physical therapy, impact, Geriatric oncology, Female, business, Randomized-trial, medicine.drug
Abstract

Purpose To study the prognostic value for overall survival of baseline assessment of functional status, comorbidity, and quality of life (QoL) in elderly patients with advanced non—small-cell lung cancer treated with chemotherapy. Patients and Methods Data from 566 patients enrolled onto the phase III randomized Multicenter Italian Lung Cancer in the Elderly Study (MILES) study were analyzed. Functional status was measured as activities of daily living (ADL) and instrumental ADL (IADL). The presence of comorbidity was assessed with a checklist of 33 items; items 29 and 30 of the European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 (EORTC QLQ-C30) were used to estimate QoL. ADL was dichotomized as none versus one or more dependency. For IADL and QoL, three categories were defined using first and third quartiles as cut points. Comorbidity was summarized using the Charlson scale. Analysis was performed by Cox model, and stratified by treatment arm. Results Better values of baseline QoL (P = .0003) and IADL (P = .04) were significantly associated with better prognosis, whereas ADL (P = .44) and Charlson score (P = .66) had no prognostic value. Performance status 2 (P = .006) and a higher number of metastatic sites (P = .02) also predicted shorter overall survival. Conclusions Pretreatment global QoL and IADL scores, but not ADL and comorbidity, have significant prognostic value for survival of elderly patients with advanced non—small-cell lung cancer who were treated with chemotherapy. Using these scores in clinical practice might improve prognostic prediction for treatment planning.

Published
2005

158. Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.)

Author

GALETTA D, GIOTTA F, ROSATI G, GEBBIA, Vittorio, MANZIONE L, DI BISCEGLIE M, BORSELLINO N, COLUCCI G, PUCCI, Ida, GALETTA D, GIOTTA F, ROSATI G, GEBBIA V, MANZIONE L, DI BISCEGLIE M, BORSELLINO N, COLUCCI G, and Pucci, I.

Subjects
Raltitrexed, Head and neck squamous cell carcinoma, Carboplatin
Abstract

ackground: The combination of cisplatin (CDDP) and 5-Fluorouracil (5-FU) is a standard regimen for the treatment of recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). This combination shows a relevant toxicity and new chemotherapy associations with a more favourable toxicity profile are awaited. Carboplatin (CB) is a platinum derivative with less toxicity than CDDP. Raltitrexed (R) is a potent and specific thymidylate synthase inhibitor with activity comparable to that of 5-FU in colorectal cancer; moreover, it showed activity as a single agent in HNSCC. Materials and Methods: Since 2001, a multicentre, phase II trial has been underway to evaluate the efficacy and toxicity of the CB+R combination in untreated patients with recurrent or metastatic HNSCC. Thirty-two patients were enrolled and included in an intent-to-treat analysis. Toxicity was graded according to NCI criteria. Patients had a histo/cytologically proven recurrent or metastatic HNSCC; patients with locally advanced disease not amenable to CDDP+5-FU treatment were also included. Patients had to be > 18 years old with ECOG PS of 0-2 and adequate bone marrow, renal and liver functions. CB (AUC 5) and R (3 mg/m 2) were administered intravenously every 3 weeks. The median age was 62 years (range 43-71), 29 M/3 F. The median PS was 1 (0-2). Twelve patients were staged III and 20 were metastatic (10 recurrent). The oral cavity/oropharynx were the primary site in 20 patients and the larynx in 10 patients. The median number of cycles delivered was 3, while globally 115 cycles were administered. The median time to progression was 4.2 months and median duration of survival was 9.8 months. Results: Seven patients achieved a partial response (22%), 10 patients showed a stable disease (31%), while 13 patients (48%) had progressive disease. Eight patients (25%) had a G 3-4 neutropenia, while G 3-4 anaemia was observed in 2 patients and thrombocytopenia in 1 patient. No extrahaematological G 3-4 toxicities were observed. A persistent G 2 hepatic toxicity led a patient to drop out from the study. Conclusion: In our phase II trial, CB in combination with R showed a moderate activity with safe administration on an outpatient basis

Published
2005

159. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

Author

GRIDELLI C, PERRONE F, CIGOLARI S, ROSSI A, PIANTEDOSI F, BARBERA S, FERRAU F, PIAZZA E, ROSETTI F, CLERICI M, BERTETTO O, ROBBIATI SF, FRONTINI L, SACCO C, CASTIGLIONE F, FAVARETTO A, NOVELLO S, MIGLIORINO MR, GASPARINI G, GALETTA D, IAFFAIOLI RV, GEBBIA V, MILES INVESTIGATORS, GALLO, Ciro, Gridelli, C, Perrone, F, Gallo, Ciro, Cigolari, S, Rossi, A, Piantedosi, F, Barbera, S, Ferrau, F, Piazza, E, Rosetti, F, Clerici, M, Bertetto, O, Robbiati, Sf, Frontini, L, Sacco, C, Castiglione, F, Favaretto, A, Novello, S, Migliorino, Mr, Gasparini, G, Galetta, D, Iaffaioli, Rv, Gebbia, V, and Miles, Investigators

Published
2003

162. Maintenance Therapy (MT) for non-squamous advanced NSCLC: a multicenter Italian survey about patients (pts)' perspectives and physicians' awareness

Author

Pacchiana, M.V., primary, Capelletto, E., additional, Rossi, A., additional, Galetta, D., additional, Bordi, P., additional, Ceribelli, A., additional, Scotti, V., additional, Cortinovis, D., additional, Valmadre, G., additional, Martelli, O., additional, Miccianza, A., additional, Del Conte, A., additional, Morena, R., additional, Rosetti, F., additional, Ostacoli, L., additional, and Novello, S., additional

Published
2015
Full Text
View/download PDF

163. Circulating-free tumor DNA as a surrogate for determination of EGFR status: the Italian experience within the ASSESS study

Author

Normanno, N., primary, Morabito, A., additional, Novello, S., additional, Cortinovis, D., additional, Migliorino, M.R., additional, Pinto, C., additional, Pasquale, R., additional, Montanino, A., additional, Capelletto, E., additional, Tonini, G., additional, Bidoli, P., additional, Galetta, D., additional, Ricciardi, S., additional, Milella, M., additional, Melotti, B., additional, Romano, G., additional, and Crinò, L., additional

Published
2015
Full Text
View/download PDF

165. Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study

Author

de Marinis, F, Ardizzoni, A, Fontanini, G, Grossi, F, Cappuzzo, F, Novello, S, Santo, A, Lorusso, V, Cortinovis, D, Iurlaro, M, Galetta, D, Gridelli, C, de Marinis, F, Ardizzoni, A, Fontanini, G, Grossi, F, Cappuzzo, F, Novello, S, Santo, A, Lorusso, V, Cortinovis, D, Iurlaro, M, Galetta, D, and Gridelli, C

Abstract

Results The longitudinal phase was conducted between January and August 2012. Of 464 patients who began second-line therapy outside of clinical trials within the baseline evaluation, 56 (12.1%) were still receiving second-line therapy at the end of the observation period and 17 (3.7%) withdrew during or after second-line therapy. Of the remaining 391 patients, 158 (40.4%) received third-line treatment outside of clinical trials: 93 received a third-line chemotherapy and 65 a targeted agent. The main reason for interrupting third-line treatment was disease progression or death. During the same observation period, 25 of 113 patients who completed a third-line therapy received a fourth line of treatment. From diagnosis of NSCLC to the end of observation, biomarkers were tested in 323 patients (59.7%): epidermal growth factor receptor mutations in 315 (58.2%), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutations in 83 (15.3%) and Anaplastic lymphoma kinase (ALK) translocation in 84 (15.5%). Conclusion In Italian clinical practice, the proportion of patients with advanced NSCLC receiving more than 2 treatment lines of therapy is not negligible. Patients and Methods In the longitudinal phase, described here, the primary aim was to determine the proportion of patients receiving third-line therapy among those who received second-line active treatment according to clinical practice. The proportion of patients receiving further treatment lines was also estimated. Introduction/Background Patients with advanced NSCLC who experience disease progression after second-line therapy might receive further active treatment. LIFE was an Italian cohort multicenter observational study composed of a cross-sectional and a longitudinal phase.

Published
2014

166. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors

Author

Landi, L, Tiseo, M, Chiari, R, Ricciardi, S, Rossi, E, Galetta, D, Novello, S, Milella, M, D'Incecco, A, Minuti, G, Tibaldi, C, Salvini, J, Facchinetti, F, Haspinger, E, Cortinovis, D, Santo, A, Banna, G, Catino, A, Giajlevra, M, Crinò, L, de Marinis, F, Cappuzzo, F, Haspinger, ER, GiajLevra, M, Landi, L, Tiseo, M, Chiari, R, Ricciardi, S, Rossi, E, Galetta, D, Novello, S, Milella, M, D'Incecco, A, Minuti, G, Tibaldi, C, Salvini, J, Facchinetti, F, Haspinger, E, Cortinovis, D, Santo, A, Banna, G, Catino, A, Giajlevra, M, Crinò, L, de Marinis, F, Cappuzzo, F, Haspinger, ER, and GiajLevra, M

Abstract

Background The purpose of this study was to evaluate the efficacy of afatinib in EGFR-mutant metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib. Materials and Methods We retrospectively analyzed the outcome of patients with EGFR-mutant advanced NSCLC treated with afatinib after failure of chemotherapy and EGFR TKIs. Results A total of 96 individuals were included in the study. According to EGFR status, most patients (n = 63; 65.6%) harbored a deletion in exon 19, and de novo T790M mutation was detected in 2 cases (T790M and exon 19). Twenty-four (25%) patients underwent repeated biopsy immediately before starting afatinib and secondary T790M was detected in 8 (33%) samples. Among the 86 patients evaluable for efficacy, response rate was 11.6%, with a median progression free-survival (PFS) and overall survival (OS) of 3.9 and 7.3 months, respectively. No significant difference in PFS and OS was observed according to type of last therapy received before afatinib, type of EGFR mutation or adherence to Jackman criteria, and patients benefiting from afatinib therapy had longer PFS and OS (P < .001). Outcome results for repeated biopsy patients were similar to the whole population, with no evidence of response in T790M-positive patients. All patients were evaluable for toxicity, and 81% experienced an AE of any grade, with grade 3 to 4 AEs, mainly diarrhea and skin toxicity, occurring in 19 (20%) patients. Conclusion Our results showed that afatinib has only modest efficacy in a real life population of EGFR mutant NSCLC patients with acquired resistance to erlotinib or gefitinib.

Published
2014

167. Advanced non-small cell lung cancer management in patients progressing after first-line treatment : results of the cross-sectional phase of the Italian LIFE observational study

Author

Gridelli, C, de Marinis, F, Ardizzoni, A, Novello, S, Fontanini, G, Cappuzzo, F, Grossi, F, Santo, A, Cortinovis, D, Favaretto, A, Lorusso, V, Galetta, D, Siena, S, Bettini, A, Iurlaro, M, Caprioli, A, Gridelli, C, de Marinis, F, Ardizzoni, A, Novello, S, Fontanini, G, Cappuzzo, F, Grossi, F, Santo, A, Cortinovis, D, Favaretto, A, Lorusso, V, Galetta, D, Siena, S, Bettini, A, Iurlaro, M, and Caprioli, A

Abstract

LIFE (non-small cell Lung cancer management In patients progressing after First-linE of treatment in the metastatic setting) is a multicentre Italian observational study, including a cross-sectional and a longitudinal phase, with the aim of describing the therapeutic approach in clinical practice for advanced non-small cell lung cancer (NSCLC) patients, progressing after first-line treatment. In this paper, the cross-sectional phase is outlined, with the primary endpoint of describing the proportion of patients receiving second-line treatment among those progressed during or after first-line treatment according to clinical practice. From July 2011 to January 2012, 603 patients were enrolled and 541 (90 %) were evaluable. A total of 464 (86 %) patients received a second-line therapy outside clinical trials. Chemotherapy and targeted therapies were administered to 65 and 34 % of patients, respectively (1 % both). No tissue collection was required within the observational trial, and biomarkers analysis was performed at diagnosis or later in 314 patients (58 %). In details, activating epidermal growth factor receptor mutations were detected in 21 % of 311 evaluable patients, Kirsten rat sarcoma 2 viral oncogene homolog mutation in 22 % of the 77 evaluable patients and anaplastic lymphoma kinase translocations analysis was performed in 74 patients and resulted positive in 23 % of cases. These high proportions were probably due to enriched patient population tested. These results showed a pattern of care for NSCLC second-line therapy which reflects international guidelines recommendations and current expected clinical practice. Interestingly, biomarkers analyses were performed in a higher percentage than expected.

Published
2014

169. E11 - The close link between anxiety and cluster symptoms in lung cancer patients during first-line chemotherapy: further data from a dedicated WALCE (Women Against Lung Cancer in Europe) survey

Author

Carnio, S., Galetta, D., Scotti, V., Cortinovis, D.L., Antonuzzo, A., Pisconti, S., Rossi, A., Martelli, O., Cecere, F.L., Lunghi, A., Del Conte, A., Montagna, E.S., Topulli, J., Pelizzoni, D., Rapetti, S.G., Gianetta, M., Pacchiana, M.V., Pegoraro, V., Cataldo, N., Bria, E., and Novello, S.

Published
2017
Full Text
View/download PDF

172. E2 - ASTRIS, a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC): preliminary analysis of the Italian cohort

Author

Passaro, A., Metro, G., Tiseo, M., Migliorino, M.R., Santo, A., Sperandi, F., Maione, P., Puppo, G., Grossi, F., Soto Parra, H.J., Borra, G., Roca, E., Rocco, D., Stasi, I., Galetta, D., Carta, A.M., Milella, M., Fasola, G., Gebbia, V., Ferrari, S., and De Marinis, F.

Published
2017
Full Text
View/download PDF

174. A safe and effective method for an immediate bronchopleural fistula repair

Author

Galetta D, Veronesi G, Solli P, Petrella F, Borri A, Roberto Gasparri, Leo F, and Spaggiari L

Subjects
Male, Lung Neoplasms, Postoperative Complications, Treatment Outcome, Amputation Stumps, Carcinoma, Squamous Cell, Humans, Bronchial Fistula, Pleural Diseases, Pneumonectomy, Aged
Abstract

Bronchopleural fistula (BPF) is a well recognized and potentially fatal complication of major thoracic surgery and several strategies regarding its prevention and subsequent management have been described. An immediate BPF occurring intraoperatively after bronchial closure is a rare event and is usually treated by bronchial stump reamputation and/or hand-suture reinforcement by mattress suture, or myoplasty. We report a simple and successful technique, using azygous vein flaps, to repair an intraoperative BPF associated to a small bronchial dehiscence occurred after a right pneumonectomy in a 70-year-old diabetic man receiving induction chemotherapy treatment.

Published
2007

175. Le situazioni giuridiche soggettive

Author

Cassese, S, Sorrentino, F, Trimarchi Banfi, F, Condinanzi, M, Nascimbene, B, Strozzi, G, Massera, A, Chiti, Mp, Franchini, C, Della Cananea, G, Cogliandro, G, Lang, A, Greco, G, Picozza, E, Cartabia, M, Onida, V, Caranta, R, and Galetta D. U., Zj

Subjects
Settore IUS/10 - Diritto Amministrativo
Published
2007

176. [Technique, results and impact of induction chemotherapy in sleeve lobectomy for lung cancer]

Author

Borri A, Leo F, Galetta D, Veronesi G, Solli P, Petrella F, Roberto Gasparri, Scanagatta P, and Spaggiari L

Subjects
Adult, Aged, 80 and over, Male, Lung Neoplasms, Anastomosis, Surgical, Suture Techniques, Bronchi, Middle Aged, Polypropylenes, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Prospective Studies, Pneumonectomy, Aged, Retrospective Studies
Abstract

The aim of this study was to evaluate the safety of continuous nonabsorbable (3/0 polypropylene) sutures for sleeve lobectomy, and the influence of induction chemotherapy on postoperative outcome in patients with lung malignancies.A review of a prospective database of a single surgeon identified 41 consecutive patients who underwent sleeve lobectomy from May 1998 to July 2003. Bronchial reconstruction was done placing two 3/0 polypropylene sutures at the far side of the cartilaginous wall and subsequently fixed. Afterwards, two running sutures were performed in order to obtain a telescopic anastomosis.Twenty-four patients (59%) underwent induction chemotherapy. There were 31 right upper, 3 left lower ''reverse'', and 7 left upper sleeve lobectomies with radical lymph node dissection. Eight patients underwent reconstruction of the pulmonary artery. There were 34 non-small cell lung cancers, 3 limited small cell lung cancers, 1 neuroendocrine large cell carcinoma, and 3 bronchial carcinoid tumors. N2, N1, and N0 diseases were found in 13, 12 and 16 patients, respectively. Post-operative morbidity and mortality were 14.5% (n=6) and 4.8% (n=2) (1 patient, 4%, after induction chemotherapy). The rate of postoperative anastomotic complications was 2.4% (n=1). Late bronchial stenosis developed in 3 cases, but all were successfully medically treated. Twenty-nine patients are still alive, 27 without evidence of disease. The overall 2-year probability of survival (Kaplan-Meier) was 59%. Induction chemotherapy did not influence postoperative morbidity/mortality (chi2 test: P=0.64/P=0.56).Continuous nonabsorbable suture for sleeve lobectomy is quick and technical easy to perform, with low postoperative morbidity/mortality; induction chemotherapy does not influence postoperative outcome in these patients.

Published
2006

177. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancerreceiving chemotherapy: a prognostic analysis of the multicenter Italian lungcancer in the elderly study

Author

Maione, P, Perrone, F, Gallo, C, Manzione, L, Piantedosi, F, Barbera, S, Cigolari, S, Rosetti, F, Piazza, E, Robbiati, Sf, Bertetto, O, Novello, S, Migliorino, Mr, Favaretto, A, Spatafora, M, Ferrau, F, Frontini, L, Bearz, A, Repetto, L, Gridelli, C, Barletta, E, Barzelloni, Ml, Iaffaioli, Rv, DE MAIO, E, DI MAIO, M, DE FEO, G, Sigoriello, G, Chiodini, P, Cioffi, A, Guardasole, V, Angelini, V, Rossi, A, Bilancia, D, Germano, D, Lamberti, A, Pontillo, V, Brancaccio, L, Renda, F, Romano, F, Esani, G, Gambaro, A, Vinante, O, Azzarello, G, Clerici, M, Bollina, R, Belloni, P, Sannicolo, M, Ciuffreda, L, Parello, G, Cabiddu, M, Sacco, C, Sibau, A, Porcile, G, Castiglione, F, Ostellino, O, Monfardini, S, Stefani, M, Scagliotti, G, Selvaggi, G, DE MARINIS, F, Martelli, O, Gasparini, G, Morabito, A, Gattuso, D, Colucci, G, Galetta, D, Giotta, F, Gebbia, V, Borsellino, N, Testa, A, Malaponte, E, Capuano, Ma, Angiolillo, M, Sollitto, F, Tirelli, U, Spazzapan, S, Adamo, Vincenzo, Altavilla, Giuseppe, Scimone, A, Hopps, Mr, Tartamella, F, Ianniello, Gp, Tinessa, V, Failla, G, Bordonaro, R, Gebbia, N, Valerio, Mr, D'Aprile, M, Veltri, E, Tonato, M, Darwish, S, Romito, S, Carrozza, F, Barni, S, Ardizzoia, A, Corradini, Gm, Pavia, G, Belli, M, Colantuoni, G, Galligioni, E, Caffo, O, Labianca, R, Quadri, A, Cortesi, E, D'Auria, G, Fava, S, Calcagno, A, Luporini, G, Locatelli, Mc, DI COSTANZO, F, Gasperoni, S, Isa, L, Candido, P, Gaion, F, Palazzolo, G, Nettis, G, Annamaria, A, Rinaldi, M, Lopez, M, Felletti, R, DI NEGRO GB, Rossi, N, Calandriello, A, Maiorino, L, Mattioli, R, Celano, A, Schiavon, S, Illiano, A, Raucci, Ca, Caruso, M, Foa, P, Tonini, G, Curcio, C, and Cazzaniga, M.

Published
2005

178. Supportive care in patients with advanced non-small-cell lung cancer

Author

DI MAIO, Massimo, Perrone, F, Gallo, C, Iaffaioli, Rv, Manzione, L, Piantedosi, Fv, Cigolari, S, Illiano, A, Barbera, S, Robbiati, Sf, Piazza, E, Ianniello, Gp, Frontini, L, Veltri, E, Castiglione, F, Rosetti, F, De Maio, E, Maione, P, Gridelli, C, Rossi, A, Barletta, E, Barzelloni, Ml, Signoriello, G, Bilancia, D, Dinota, A, Rosati, G, Germano, D, Lamberti, A, Pontillo, V, Brancacio, L, Crispino, C, Esposito, M, Battiloro, C, Tufano, G, Cioffi, A, Guardasole, V, Angelini, V, Guidetti, G, Renda, F, Romano, F, Volpintesta, A, Sannicolò, M, Filipazzi, V, Esani, G, Gambaro, A, Ferrario, S, Tinessa, V, Caprio, Mg, Zonato, S, Cabiddu, M, Raina, A, D'Aprile, M, Pistillucci, G, Porcile, G, Ostellino, O, Vinante, O, Azzarello, G, Gebbia, V, Borsellino, N, Testa, A, Gasparini, G, Morabito, A, Gattuso, D, Romito, S, Carrozza, F, Fava, S, Calcagno, A, Grimi, E, Bertetto, O, Ciuffreda, L, Parello, G, Maiorino, L, Santoro, A, Santoro, M, Failla, G, Aiello, Ra, Bearz, A, Sorio, R, Scalone, S, Clerici, M, Bollina, R, Belloni, P, Sacco, C, Sibau, A, Adamo, V, Altavilla, G, Scimone, A, Spatafora, M, Bellia, V, Hopps, Mr, Monfardini, S, Favaretto, A, Stefani, M, Corradini, Gm, Pavia, G, Scagliotti, Giorgio Vittorio, Novello, Silvia, Selvaggi, G, Tonato, M, Darwish, S, Michetti, G, Belometti, Mo, Labianca, R, Quadri, A, De Marinis, F, Migliorino, Mr, Martelli, O, Colucci, G, Galetta, D, Giotta, F, Isa, L, Candido, P, Rossi, N, Calandriello, A, Ferraù, F, Malaponte, E, Barni, S, Cazzaniga, M, Gebbia, N, Valerio, Mr, Belli, M, Colantuoni, G, Capuano, Ma, Angiolillo, M, Sollitto, F, Ardizzoia, A, Luporini, G, Locatelli, Mc, Pari, F, Aitini, E, Pedicini, T, Febbraro, A, Zollo, C, Di Costanzo, F, Bartolucci, R, Gasperoni, S, Gaion, F, Palazzolo, G, Galligioni, E, Caffo, O, Cortesi, E, D'Auria, G, Curcio, C, Vasta, M, Bumma, C, Celano, A, Bretti, S, Nettis, G, Anselmo, A, Mattioli, R, Nisticò, C, Aschelter, A, Foa, P., DI MAIO, M, Perrone, F, Gallo, Ciro, Iaffaioli, Rv, Manzione, L, Piantedosi, Fv, Cigolari, S, Illiano, A, Barbera, S, Robbiati, Sf, Piazza, E, Ianniello, Gp, Frontini, L, Veltri, E, Castiglione, F, Rosetti, F, DE MAIO, E, Maione, P, and Gridelli, C.

Subjects
Adult, Male, concomitant drugs, Cancer Research, medicine.medical_specialty, Aging, Palliative care, Lung Neoplasms, medicine.medical_treatment, Vinorelbine, Vinblastine, Deoxycytidine, Clinical, Quality of life, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, polypharmacotherapy, medicine, Humans, Lung cancer, Survival rate, Aged, Randomized Controlled Trials as Topic, Aged, 80 and over, Chemotherapy, Performance status, business.industry, Palliative Care, Middle Aged, medicine.disease, Gemcitabine, Surgery, Survival Rate, supportive care, lung cancer, Oncology, Concomitant, Quality of Life, Antiemetics, Female, Cisplatin, business, medicine.drug
Abstract

The present study describes supportive care (SC) in patients with advanced non-small-cell lung cancer (NSCLC), evaluating whether it is affected by concomitant chemotherapy, patient's performance status (PS) and age. Data of patients enrolled in three randomised trials of first-line chemotherapy, conducted between 1996 and 2001, were pooled. The analysis was limited to the first three cycles of treatment. Supportive care data were available for 1185 out of 1312 (90%) enrolled patients. Gastrointestinal drugs (45.7%), corticosteroids (33.4%) and analgesics (23.8%) were the most frequently observed categories. The mean number of drugs per patient was 2.43; 538 patients (45.4%) assumed three or more supportive drugs. Vinorelbine does not produce substantial variations in the SC pattern, while cisplatin-based treatment requires an overall higher number of supportive drugs, with higher use of antiemetics (41 vs 27%) and antianaemics (10 vs 4%). Patients with worse PS are more exposed to corticosteroids (42 vs 30%). Elderly patients require drugs against concomitant diseases significantly more than adults (20 vs 7%) and are less frequently exposed to antiemetics (12 vs 27%). In conclusion, polypharmacotherapy is a relevant issue in patients with advanced NSCLC. Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults.

Published
2004

179. Be-Positive: Beyond Progression After Tyrosine Kinase Inhibitor in Egfr-Positive Non-Small Cell Lung Cancer (Nsclc) Patients. Preliminary Results from a Multicenter Italian Observational Study

Author

Vavala, T., primary, Follador, A., additional, Tiseo, M., additional, Galetta, D., additional, Montanino, A., additional, Martelli, O., additional, Caffo, O., additional, Piovano, P.L., additional, Cortinovis, D., additional, Zilembo, N., additional, Casartelli, C., additional, Banna, G., additional, Colombo, D., additional, Barzelloni, M.L., additional, Rijavec, E., additional, Cecere, F.L., additional, Bria, E., additional, Lazzari, C., additional, Rossi, A., additional, and Novello, S., additional

Published
2014
Full Text
View/download PDF

181. Operative rigid bronchoscopy: indications, basic techniques and results

Author

Petrella, F., primary, Borri, A., additional, Casiraghi, M., additional, Cavaliere, S., additional, Donghi, S., additional, Galetta, D., additional, Gasparri, R., additional, Guarize, J., additional, Pardolesi, A., additional, Solli, P., additional, Tessitore, A., additional, Venturino, M., additional, Veronesi, G., additional, and Spaggiari, L., additional

Published
2014
Full Text
View/download PDF

182. Grading the neuroendocrine tumors of the lung: an evidence-based proposal

Author

Rindi, G, primary, Klersy, C, additional, Inzani, F, additional, Fellegara, G, additional, Ampollini, L, additional, Ardizzoni, A, additional, Campanini, N, additional, Carbognani, P, additional, De Pas, T M, additional, Galetta, D, additional, Granone, P L, additional, Righi, L, additional, Rusca, M, additional, Spaggiari, L, additional, Tiseo, M, additional, Viale, G, additional, Volante, M, additional, Papotti, M, additional, and Pelosi, G, additional

Published
2014
Full Text
View/download PDF

183. Supportive care in patients with advanced non small cell lung cancer

Author

DI MAIO, M, Perrone, F, Gallo, C, Iaffaioli, Rv, Manzione, L, Piantedosi, Fv, Cigolari, S, Illiano, A, Barbera, S, Robbiati, Sf, Piazza, E, Ianniello, Gp, Frontini, L, Veltri, E, Castiglione, F, Rosetti, F, DE MAIO, E, Maione, P, Gridelli, C, Rossi, A, Barletta, E, Barzelloni, Ml, Signoriello, G, Bilancia, D, Dinota, A, Rosati, G, Germano, D, Lamberti, A, Pontillo, V, Brancacio, L, Crispino, C, Esposito, M, Battiloro, C, Tufano, G, Cioffi, A, Guardasole, V, Angelini, V, Guidetti, G, Renda, F, Romano, F, Volpintesta, A, Sannicolo, M, Filipazzi, V, Esani, G, Gambaro, A, Ferrario, S, Tinessa, V, Caprio, Mg, Zonato, S, Cabiddu, M, Raina, A, D'Aprile, M, Pistillucci, G, Porcile, G, Ostellino, O, Vinante, O, Azzarello, G, Gebbia, V, Borsellino, N, Testa, A, Gasparini, G, Morabito, A, Gattuso, D, Romito, S, Carrozza, F, Fava, S, Calcagno, A, Grimi, E, Bertetto, O, Ciuffreda, L, Parello, G, Maiorino, L, Santoro, A, Santoro, M, Failla, G, Aiello, Ra, Bearz, A, Sorio, R, Scalone, S, Clerici, M, Bollina, R, Belloni, P, Sacco, C, Sibau, A, Adamo, Vincenzo, Altavilla, Giuseppe, Scimone, A, Spatafora, M, Bellia, V, Hopps, Mr, Monfardini, S, Favaretto, A, Stefani, M, Corradini, Gm, Pavia, G, Scagliotti, G, Novello, S, Selvaggi, G, Tonato, M, Darwish, S, Michetti, G, Belometti, Mo, Labianca, R, Quadri, A, DE MARINIS, F, Migliorino, Mr, Martelli, O, Colucci, G, Galetta, D, Giotta, F, Isa, L, Candido, P, Rossi, N, Calandriello, A, Ferrau, F, Malaponte, E, Barni, S, Cazzaniga, M, Gebbia, N, Valerio, Mr, Belli, M, Colantuoni, G, Capuano, Ma, Angiolillo, M, Sollitto, F, Ardizzoia, A, Luporini, G, Locatelli, Mc, Pari, F, Aitini, E, Pedicini, T, Febbraro, A, Zollo, C, DI COSTANZO, F, Bartolucci, R, Gasperoni, S, Gaion, F, Palazzolo, G, Galligioni, E, Caffo, O, Cortesi, E, D'Auria, G, Curcio, C, Vasta, M, Bumma, C, Celano, A, Bretti, S, Nettis, G, Anselmo, A, Mattioli, R, Nistico, C, Aschelter, A, and Foa, P.

Published
2003

184. Grading the neuroendocrine tumors of the lung: an evidence-based proposal.

Author

Granone, Pierluigi, Rindi, Guido, Inzani, Frediano, Klersy, C, Fellegara, G, Ampollini, L, Ardizzoni, A, Campanini, N, Carbognani, P, De Pas, Tm, Galetta, D, Righi, L, Rusca, M, Spaggiari, L, Tiseo, M, Volante, M, Papotti, M, Pelosi, G., Granone, Pierluigi (ORCID:0000-0002-8826-3045), Rindi, Guido (ORCID:0000-0003-2996-4404), Granone, Pierluigi, Rindi, Guido, Inzani, Frediano, Klersy, C, Fellegara, G, Ampollini, L, Ardizzoni, A, Campanini, N, Carbognani, P, De Pas, Tm, Galetta, D, Righi, L, Rusca, M, Spaggiari, L, Tiseo, M, Volante, M, Papotti, M, Pelosi, G., Granone, Pierluigi (ORCID:0000-0002-8826-3045), and Rindi, Guido (ORCID:0000-0003-2996-4404)

Abstract

Lung neuroendocrine tumors are catalogued in four categories by the World Health Organization (WHO 2004) classification. Its reproducibility and prognostic efficacy was disputed. The WHO 2010 classification of digestive neuroendocrine neoplasms is based on Ki67 proliferation assessment and proved prognostically effective. This study aims at comparing these two classifications and at defining a prognostic grading system for lung neuroendocrine tumors. The study included 399 patients who underwent surgery and with at least 1 year follow-up between 1989 and 2011. Data on 21 variables were collected, and performance of grading systems and their components was compared by Cox regression and multivariable analyses. All statistical tests were two-sided. At Cox analysis, WHO 2004 stratified patients into three major groups with statistically significant survival difference (typical carcinoid vs atypical carcinoid (AC), P=0.021; AC vs large-cell/small-cell lung neuroendocrine carcinomas, P<0.001). Optimal discrimination in three groups was observed by Ki67% (Ki67% cutoffs: G1 <4, G2 4-<25, G3 ≥25; G1 vs G2, P=0.021; and G2 vs G3, P≤0.001), mitotic count (G1 ≤2, G2 >2-47, G3 >47; G1 vs G2, P≤0.001; and G2 vs G3, P≤0.001), and presence of necrosis (G1 absent, G2 <10% of sample, G3 >10% of sample; G1 vs G2, P≤0.001; and G2 vs G3, P≤0.001) at uni and multivariable analyses. The combination of these three variables resulted in a simple and effective grading system. A three-tiers grading system based on Ki67 index, mitotic count, and necrosis with cutoffs specifically generated for lung neuroendocrine tumors is prognostically effective and accurate.

Published
2013

188. Malignant solitary fibrous tumors of the pleura: retrospective review of a multicenter series

Author

Lococo, Filippo, Cesario, Alfredo, Cardillo, G, Filosso, P, Galetta, D, Carbone, Lorenzo, Oliaro, A, Spaggiari, L, Cusumano, Giacomo, Margaritora, Stefano, Graziano, Paola, Granone, Pierluigi, Lococo, Filippo Maria (ORCID:0000-0002-9383-5554), Cesario, Alfredo (ORCID:0000-0003-4687-0709), Margaritora, Stefano (ORCID:0000-0002-9796-760X), Granone, Pierluigi (ORCID:0000-0002-8826-3045), Lococo, Filippo, Cesario, Alfredo, Cardillo, G, Filosso, P, Galetta, D, Carbone, Lorenzo, Oliaro, A, Spaggiari, L, Cusumano, Giacomo, Margaritora, Stefano, Graziano, Paola, Granone, Pierluigi, Lococo, Filippo Maria (ORCID:0000-0002-9383-5554), Cesario, Alfredo (ORCID:0000-0003-4687-0709), Margaritora, Stefano (ORCID:0000-0002-9796-760X), and Granone, Pierluigi (ORCID:0000-0002-8826-3045)

Abstract

Available data on the malignant solitary fibrous tumor of the pleura (mSFTP), a very rare neoplasm with unpredictable prognosis, are scarce. The aim of this study is to collectively analyze the aggregated data from the largest series in the English literature to date, a multicenter, 10-year study of 50-cases.

Published
2012

190. 1235P - Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)

Author

Normanno, N., Rachiglio, A.M., Lambiase, M., Fenizia, F., Iannaccone, A., Chicchinelli, N., Morabito, A., Montanino, A., Rocco, G., Galetta, D., Montagna, E.S., Crinò, L., Ludovini, V., Vincenzi, B., Barletta, E., Pinto, C., Ferraù, F., Botti, G., Piccirillo, M.C., and Perrone, F.

Published
2016
Full Text
View/download PDF

192. A21 - Chemotherapy-induced nausea and vomiting (CINV) in patients with stage III/IV lung cancer during the first-line treatment: assessment by physician, nurse and patient. Preliminary results from an Italian multicenter survey

Author

Carnio, S., Galetta, D., Scotti, V., Cortinovis, D.L., Antonuzzo, A., Pisconti, S., Rossi, A., Martelli, O., Cecere, F.L., Bria, E., Del Conte, A., Pegoraro, V., Montagna, E.S., Topulli, J., Pelizzoni, D., Rapetti, S.G., Gianetta, M., and Novello, S.

Published
2016
Full Text
View/download PDF

196. A03* - Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)

Author

Normanno, N., Rachiglio, A.M., Lambiase, M., Fenizia, F., Iannaccone, A., Chicchinelli, N., Morabito, A., Rocco, G., Galetta, D., Montagna, E.S., Crinò, L., Ludovini, V., Vincenzi, B., Barletta, E., Pinto, C., Ferraù, F., Botti, G., Piccirillo, M.C., and Perrone, F.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results